Dentists are often the first health professionals to see children with arthritis because the temporomandibular joints (TMJ) that enable chewing ...
The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.
Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback